Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

U. Vaishampayan, P. Schöffski, A. Ravaud, C. Borel, J. Peguero, J. Chaves, JC. Morris, N. Kotecki, M. Smakal, D. Zhou, S. Guenther, M. Bajars, JL. Gulley,

. 2019 ; 7 (1) : 275. [pub] 20191024

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze I, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025572

BACKGROUND: Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti-PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment. METHODS: Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety. RESULTS: A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8-not evaluable) and not evaluable (95% CI, 6.9-not evaluable), median PFS was 8.3 months (95% CI, 5.5-9.5) and 5.6 months (95% CI, 2.3-9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3-not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred. CONCLUSION: Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01772004 ; registered 21 January, 2013.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025572
003      
CZ-PrNML
005      
20201222153955.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40425-019-0746-2 $2 doi
035    __
$a (PubMed)31651359
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vaishampayan, Ulka $u Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI, 48201, USA. vaishamu@karmanos.org.
245    10
$a Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial / $c U. Vaishampayan, P. Schöffski, A. Ravaud, C. Borel, J. Peguero, J. Chaves, JC. Morris, N. Kotecki, M. Smakal, D. Zhou, S. Guenther, M. Bajars, JL. Gulley,
520    9_
$a BACKGROUND: Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti-PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment. METHODS: Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety. RESULTS: A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8-not evaluable) and not evaluable (95% CI, 6.9-not evaluable), median PFS was 8.3 months (95% CI, 5.5-9.5) and 5.6 months (95% CI, 2.3-9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3-not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred. CONCLUSION: Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01772004 ; registered 21 January, 2013.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a protinádorové látky imunologicky aktivní $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000074322
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schöffski, Patrick $u General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
700    1_
$a Ravaud, Alain $u Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
700    1_
$a Borel, Christian $u Medical Oncology, Centre Paul Strauss, Centre de Recherche, Centres de Lutte Contre le Cancer (CRLCC), Strasbourg, France.
700    1_
$a Peguero, Julio $u Oncology Haematology, Oncology Consultants, Houston, USA.
700    1_
$a Chaves, Jorge $u Haematology-Oncology, Northwest Medical Specialties, Lakewood, USA.
700    1_
$a Morris, John C $u Internal Medicine, University of Cincinnati, Cincinnati, USA.
700    1_
$a Kotecki, Nuria $u Centre Oscar Lambret, Lille, France.
700    1_
$a Smakal, Martin $u Horovice Oncology Clinic, Nemocnice Rudolfa a Stefanie Benešov, a. s, Benešov, Czech Republic.
700    1_
$a Zhou, Dongli $u Merck Serono Pharmaceutical R&D Co, Beijing, China.
700    1_
$a Guenther, Silke $u Merck KGaA, Darmstadt, Germany.
700    1_
$a Bajars, Marcis $u Global Clinical Development, EMD Serono, Billerica, USA.
700    1_
$a Gulley, James L $u Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
773    0_
$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 7, č. 1 (2019), s. 275
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31651359 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153951 $b ABA008
999    __
$a ok $b bmc $g 1599717 $s 1116258
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 1 $d 275 $e 20191024 $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace